Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Other Accumulated Expenses (2016 - 2026)

Protara Therapeutics' Other Accumulated Expenses history spans 12 years, with the latest figure at $176000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 22.12% to $176000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $176000.0 through Mar 2026, down 22.12% year-over-year, with the annual reading at $279000.0 for FY2025, 106.67% up from the prior year.
  • Other Accumulated Expenses came in at $176000.0 for Q1 2026, down from $279000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $368000.0 in Q3 2024 to a low of $79000.0 in Q1 2022.
  • The 5-year median for Other Accumulated Expenses is $178000.0 (2022), against an average of $192235.3.
  • Year-over-year, Other Accumulated Expenses tumbled 71.99% in 2022 and then skyrocketed 354.32% in 2024.
  • Protara Therapeutics' Other Accumulated Expenses stood at $182000.0 in 2022, then fell by 1.1% to $180000.0 in 2023, then dropped by 25.0% to $135000.0 in 2024, then skyrocketed by 106.67% to $279000.0 in 2025, then tumbled by 36.92% to $176000.0 in 2026.
  • Per Business Quant, the three most recent readings for TARA's Other Accumulated Expenses are $176000.0 (Q1 2026), $279000.0 (Q4 2025), and $329000.0 (Q3 2025).